Melanoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Melanoma
- Therapeutic area
- Oncology
- melanoma
- malignant melanoma
- melanoma
- melanoma (disease)
- melanoma, malignant
- Disease mechanisms
- Developmental
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0005105
- Parent condition
- MONDO:0021143
Related records
Broader conditions (10)
- Cancer or benign tumor
- Disease
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disorder of development or morphogenesis
- Human disease
- Melanocytic neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Neurocristopathy
Narrower conditions (69)
- Acral lentiginous melanoma
- Adult leptomeningeal melanoma
- Amelanotic melanoma
- Amelanotic skin melanoma
- Anal melanoma
- Balloon cell malignant melanoma
- CDK4 linked melanoma
- Cervix melanoma
- Childhood malignant melanoma
- Choroid epithelioid cell melanoma
- Choroid mixed cell melanoma
- Choroid necrotic melanoma
- Choroid spindle cell melanoma
- Ciliary body epithelioid cell melanoma
- Ciliary body mixed cell melanoma
- Ciliary body spindle cell melanoma
- Cutaneous melanoma
- Desmoplastic melanoma
- Digestive system melanoma
- Epithelioid cell melanoma
Trials (3,253)
- 'Cancer Patients Better Life Experience'
- "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
- (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma
- [18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis
- [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
- 0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma
- 131-I-TM-601 Study in Adults With Solid Tumors
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- 18F-FLT PET Imaging in Patients With Advanced Melanoma
- 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
- 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
- 18F-Labeled Picolinamide PET Imaging of Melanoma Diagnosis
- 18FDG PET for Early Identification of Tumor Exhaust for Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Bronchopulmonary Carcinoma or Melanoma
- 18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy
- 3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With Melanoma
- 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
- 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results
- 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- 7T MRI Scan for the Early Detection of Melanoma Brain Metastases
Approved drugs (18)
- Aldesleukin
- Binimetinib
- Cobimetinib fumarate
- Dabrafenib mesylate
- Dacarbazine
- Encorafenib
- Hydroxyurea
- Interferon alfa-2B
- Ipilimumab
- Lifileucel
- Nivolumab
- Peginterferon alfa-2B
- Pembrolizumab
- Talimogene laherparepvec
- Tebentafusp
- Technetium TC 99M sulfur colloid
- Trametinib dimethyl sulfoxide
- Vemurafenib
Drugs in development (375)
- .ALPHA.-pyrrolidinononanophenone Phase 1
- Abemaciclib Phase 2
- ABX-IL8 Phase 2
- ABX-MA1 Phase 1
- Acenocoumarol Phase 1
- Acetylcysteine Phase 2
- Acitretin Phase 2
- Adakitug Phase 1
- Adenosine diphosphate Phase 1
- Aflibercept Phase 3
- Agatolimod sodium Phase 2
- Alectinib Phase 2
- AN-9 Phase 1
- Antineoplaston A10 Phase 2
- AS-1409 Phase 1
- Astuprotimut-R Phase 2
- Atezolizumab Phase 3
- Autogene cevumeran Phase 2
- Avadomide Phase 2
- Avelumab Phase 1
Other linked drugs (11)
- Allantoin
- Fruquintinib
- FX-005
- Imcnyeso
- Interferon alfa-N3
- Nelitolimod
- Pimonidazole
- Tilmanocept
- Tucidinostat
- Vodudeutentan sodium
- Withaferin A